Paxlovid
-
Pfizer Shaves Revenue Projections, Starts Cost-Cutting Plan Amid Lower Covid-19 Product Demand
Pfizer lowered its revenue projections for 2023, a change it attributed to declining demand for its Covid-19 vaccine, Comirnaty, and antiviral drug, Paxlovid. Citing this revenue decline, Pfizer is implementing a companywide cost-cutting plan projected to save $3.5 billion.
-
Jorie Healthcare CEO Shares Why Automation is Critical to Revenue Cycle Management
The revenue cycle management business is using AI tools to automate cumbersome tasks to help hospitals operate more efficiently. It’s beginning to attract the attention of major healthcare organizations.
-
FDA says pharmacists can prescribe Covid treatment
The AMA believes physicians should still be the main prescribers, while advocates for provider status for pharmacists say it’s a win for health equity and will expand treatment access.
-
Covid-19 roundup: Boosters for kids, CAR-NK cell therapy, Paxlovid rebound & more
Pfizer and BioNTech reported positive clinical data for a Covid-19 booster in children younger than 5, results released ahead of a June FDA advisory committee meeting scheduled to discuss the use of that vaccine and Moderna’s in kids. In other Covid news this week, the CDC issued a health advisory for Pfizer’s antiviral Paxlovid and a respiratory failure drug for Covid-19 flunked its clinical trial.